Improved Overall Survival in Melanoma with Combined Dabrafenib and TrametinibCaroline Robert, Dirk Schadendorf, Ivana Krajsová et al.|New England Journal of Medicine|2014Cited by 2.7k
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialJean‐Jacques Grob, Caroline Robert, Mayur M. Amonkar et al.|The Lancet Oncology|2015Cited by 264
3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanomaCaroline Robert, Dirk Schadendorf, Bogusława Karaszewska et al.|European Journal of Cancer|2015Cited by 80
Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanomaCaroline Robert, Dirk Schadendorf, Bogusława Karaszewska et al.|Annals of Oncology|2016Cited by 74
Combi-V: a Randomised, Open-Label, Phase III Study Comparing the Combination of Dabrafenib (D) and Trametinib (T) with Vemurafenib (V) As First-Line Therapy in Patients (Pts) with Unresectable or Metastatic Braf V600E/K Mutation-Positive Cutaneous MelanomaCaroline Robert, Dirk Schadendorf, Bogusława Karaszewska et al.|Annals of Oncology|2014Cited by 7